Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020
22 juin 2020 08h30 HE | Ascendis Pharma
- In vitro data demonstrated selective binding and activation of IL-2 β/γ receptor, associated with reduced IL-2 α receptor binding - - Selective expansion and activation of cells in vivo consistent...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results
18 nov. 2019 16h01 HE | Ascendis Pharma
– Continued execution of global endocrinology rare disease programs as planned regulatory filings for TransCon™ hGH in 2020 advance on track – – Expanded PaTH Forward Trial expedites enrollment of...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019
06 nov. 2019 16h02 HE | Ascendis Pharma A/S
– A single dose of TransCon TLR7/8 Agonist demonstrated sustained localized release of active drug over weeks and potent anti-tumor activity when administered directly into the tumor – ...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma A/S Announces Poster Presentation on TransCon Technology at the Controlled Release Society Annual Meeting
23 juil. 2018 16h44 HE | Ascendis Pharma A/S
COPENHAGEN, Denmark, July 23, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...